INAB News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IN

Volume

30.46K

Next Earnings

November 5th

Loading chart

IN

INABIN8bio, Inc. Common Stock

INAB

Pay with—

Available Balance0.00

IN

Mkt Cap

$11.7M

Volume

30.46K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)IN8bio, Inc. (Nasdaq: INAB) announced that its Compensation Committee granted a new employee nonqualified stock options to purchase 60,000 shares of common stock as an inducement to join the company. The options vest over four years with 25% vesting on the first anniversary and the remainder in equal monthly installments thereafter.GlobeNewswire Inc. · Oct 6, 2026

IN8bio to Present at Sidoti Small-Cap Virtual ConferenceIN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies, announced that CEO William Ho will present at the Sidoti Small-Cap Virtual Conference on September 24, 2026. The presentation will cover the company's differentiated γδ T cell platform and pipeline, including lead program INB-619 and clinical-stage oncology programs.GlobeNewswire Inc. · Sep 22, 2026

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed GlioblastomaIN8bio announced peer-reviewed clinical results from its Phase 1 trial of INB-200 (DeltEx DRI) published in The Journal of Clinical Oncology. The chemotherapy-resistant gamma-delta T cell therapy demonstrated a median progression-free survival of 16.1 months in repeat-dose patients, more than double the standard of care benchmark of 6.9 months, with no dose-limiting toxicities. The therapy showed a well-tolerated safety profile and median overall survival of 19.5 months in repeat-dose patients.GlobeNewswire Inc. · Jul 9, 2026

IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical ConferencesIN8bio announced presentations at major medical conferences in May-June 2026, including new clinical data on its gamma-delta T cell therapies at ASCO. The company will host an R&D Day on May 21, 2026, showcasing advances in its T cell engager platform and clinical programs, particularly highlighting survival benefits observed in glioblastoma patients treated with DeltEx DRI.GlobeNewswire Inc. · May 6, 2026

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)IN8bio, Inc. (Nasdaq: INAB) announced that its Compensation Committee granted nonqualified stock options for 11,800 shares of common stock to two new employees on April 1, 2026, as an inducement for employment. The options will vest over four years with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments.GlobeNewswire Inc. · Apr 3, 2026

INB.bio Launches 2026 Growth Strategy With New Market Entries Across Africa, MENA and Southeast AsiaINB.bio, a direct advertiser in dietary and wellness supplements operating across 15 countries, announced its 2026 expansion strategy targeting Tanzania and three to five additional countries in Africa and Southeast Asia. The company plans to launch an AI-powered affiliate CRM platform and a turnkey partner program. The expansion capitalizes on accelerating global wellness demand, projected to reach $9.8 trillion by 2029, with significant growth opportunities in emerging markets.GlobeNewswire Inc. · Mar 23, 2026

IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating OfficerIN8bio announced the promotion of Kate Rochlin, Ph.D., to President and Chief Operating Officer, effective immediately. Dr. Rochlin, who has served as COO since December 2021, will continue overseeing company operations as IN8bio advances its clinical pipeline. The company highlighted recent preclinical data for INB-619, its pan-γδ T cell engager, which achieved complete B cell depletion with minimal adverse effects, validating the differentiation of its T cell engager platform.GlobeNewswire Inc. · Feb 9, 2026

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business HighlightsIN8bio reported financial results and highlighted preclinical data on INB-619, a novel gamma-delta T cell engager, demonstrating potential for deep B cell depletion with minimal adverse effects. The company expanded its INB-100 Phase 1 clinical trial to The Ohio State University and continues advancing its T cell therapy platform.GlobeNewswire Inc. · Nov 6, 2025

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New SiteIN8bio announced The Ohio State University as a new clinical site for its Phase 1 trial of INB-100, a gamma-delta T cell therapy for leukemia patients undergoing stem cell transplantation. The trial aims to explore strategies for reducing graft-versus-host disease and relapse risks.GlobeNewswire Inc. · Oct 29, 2025

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma TrialIN8bio's gamma-delta T cell therapy INB-200 has demonstrated a significant clinical milestone, with a patient with a grade 4, IDH-mutant glioma remaining in remission and progression-free for 4 years after treatment. This outcome highlights the potential of INB-200 in treating this aggressive and deadly cancer.GlobeNewswire Inc. · Jun 9, 2025

to start trading

IN

INABIN8bio, Inc. Common Stock

INAB

Pay with—

Available Balance0.00

Your PositionYou don't own any INAB yet.

Related Tickers

Earnings